Biohaven Ltd. (NYSE:BHVN) Shares Sold by Raymond James & Associates

Raymond James & Associates cut its holdings in shares of Biohaven Ltd. (NYSE:BHVNGet Rating) by 67.0% during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 12,070 shares of the company’s stock after selling 24,559 shares during the period. Raymond James & Associates’ holdings in Biohaven were worth $1,825,000 as of its most recent SEC filing.

Other institutional investors have also recently modified their holdings of the company. US Bancorp DE increased its holdings in Biohaven by 19.1% in the 1st quarter. US Bancorp DE now owns 586 shares of the company’s stock worth $70,000 after acquiring an additional 94 shares in the last quarter. Palladiem LLC grew its position in shares of Biohaven by 10.5% in the second quarter. Palladiem LLC now owns 1,895 shares of the company’s stock valued at $276,000 after purchasing an additional 180 shares during the period. EverSource Wealth Advisors LLC increased its stake in shares of Biohaven by 311.8% during the second quarter. EverSource Wealth Advisors LLC now owns 280 shares of the company’s stock worth $41,000 after purchasing an additional 212 shares in the last quarter. Cetera Advisor Networks LLC raised its position in shares of Biohaven by 8.1% during the 2nd quarter. Cetera Advisor Networks LLC now owns 3,030 shares of the company’s stock worth $442,000 after purchasing an additional 226 shares during the last quarter. Finally, Chartwell Investment Partners LLC lifted its stake in Biohaven by 2.6% in the 2nd quarter. Chartwell Investment Partners LLC now owns 10,741 shares of the company’s stock valued at $1,565,000 after buying an additional 268 shares in the last quarter. 98.01% of the stock is currently owned by institutional investors and hedge funds.

Biohaven Stock Down 2.4 %

BHVN stock opened at $18.73 on Wednesday. Biohaven Ltd. has a 52-week low of $5.54 and a 52-week high of $20.00. The stock has a market cap of $1.28 billion, a price-to-earnings ratio of -1.34 and a beta of 1.05. The business has a fifty day moving average of $15.44 and a two-hundred day moving average of $72.20.

Biohaven (NYSE:BHVNGet Rating) last announced its quarterly earnings results on Wednesday, November 9th. The company reported ($1.75) EPS for the quarter, beating the consensus estimate of ($2.53) by $0.78. As a group, sell-side analysts anticipate that Biohaven Ltd. will post -9.82 EPS for the current year.

Insiders Place Their Bets

In other news, CEO Vlad Coric purchased 41,930 shares of the firm’s stock in a transaction on Friday, October 28th. The shares were bought at an average cost of $14.87 per share, for a total transaction of $623,499.10. Following the completion of the purchase, the chief executive officer now directly owns 1,517,594 shares of the company’s stock, valued at $22,566,622.78. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 12.40% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

Several equities research analysts have commented on the company. SVB Securities started coverage on Biohaven in a report on Tuesday. They set an “outperform” rating and a $24.00 target price for the company. JPMorgan Chase & Co. initiated coverage on Biohaven in a research note on Wednesday, January 4th. They issued an “overweight” rating and a $23.00 price objective for the company. SVB Leerink initiated coverage on shares of Biohaven in a research note on Tuesday. They set an “outperform” rating and a $24.00 target price on the stock. Cowen dropped their target price on shares of Biohaven to $25.00 in a report on Monday, November 7th. Finally, Cowen set a $25.00 price target on shares of Biohaven in a research report on Monday, November 7th. Three analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $58.32.

Biohaven Company Profile

(Get Rating)

Biohaven Ltd., a clinical-stage biopharmaceutical company, focuses on discovering and developing therapies for patients with debilitating neurological and neuropsychiatric diseases in the United States. The company's pipeline products include BHV-7000, a potassium channel activator for the treatment of focal epilepsy; Troriluzole, a tripeptide prodrug that is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500, a low-trapping glutamate N-methyl-D-aspartate receptor antagonist for neuropathic pain; and Verdiperstat, an irreversible myeloperoxidase enzyme inhibitor for the treatment of neurodegenerative diseases.

Further Reading

Want to see what other hedge funds are holding BHVN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Biohaven Ltd. (NYSE:BHVNGet Rating).

Institutional Ownership by Quarter for Biohaven (NYSE:BHVN)

Receive News & Ratings for Biohaven Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biohaven and related companies with MarketBeat.com's FREE daily email newsletter.